Repligen Corporation $RGEN Shares Purchased by Comerica Bank

Key Points

• Comerica Bank increased its stake in Repligen Corporation by 18.3%, owning approximately $12.7 million worth of shares after acquiring additional stocks, showing strong institutional interest in the company.
• Repligen reported $182.37 million in revenue for the last quarter, exceeding analysts' expectations and marking a 14.8% year-over-year increase, although it posted a slight earnings miss with $0.37 EPS.
• Analysts have mixed ratings on Repligen, with an average consensus price target of $169.45, indicating a generally favorable outlook despite varied target adjustments from different financial firms.

Comerica Bank grew its stake in Repligen Corporation (NASDAQ:RGEN - Free Report) by 18.3% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 99,800 shares of the biotechnology company's stock after buying an additional 15,408 shares during the quarter. Comerica Bank owned 0.18% of Repligen worth $12,699,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of RGEN. Alliance Wealth Advisors LLC UT lifted its holdings in Repligen by 2.5% in the first quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company's stock valued at $468,000 after acquiring an additional 89 shares during the period. Utah Retirement Systems lifted its stake in shares of Repligen by 1.1% in the 4th quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company's stock valued at $1,338,000 after purchasing an additional 100 shares during the period. State of Michigan Retirement System lifted its stake in shares of Repligen by 0.8% in the 1st quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company's stock valued at $1,585,000 after purchasing an additional 100 shares during the period. Louisiana State Employees Retirement System lifted its stake in shares of Repligen by 0.7% in the 1st quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company's stock valued at $1,858,000 after purchasing an additional 100 shares during the period. Finally, Signaturefd LLC raised its position in shares of Repligen by 65.3% in the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock worth $41,000 after acquiring an additional 128 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Price Performance

Shares of NASDAQ:RGEN traded up $0.15 during midday trading on Friday, hitting $122.32. The company had a trading volume of 651,937 shares, compared to its average volume of 736,852. Repligen Corporation has a twelve month low of $102.96 and a twelve month high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The stock has a market cap of $6.88 billion, a price-to-earnings ratio of -489.26, a price-to-earnings-growth ratio of 2.25 and a beta of 1.05. The business's 50-day simple moving average is $121.74 and its 200-day simple moving average is $130.21.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The company had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. During the same period in the prior year, the business posted $0.40 EPS. Repligen's revenue for the quarter was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, research analysts predict that Repligen Corporation will post 1.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

RGEN has been the subject of a number of analyst reports. Wall Street Zen downgraded shares of Repligen from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Stephens raised Repligen to an "overweight" rating and set a $160.00 price target for the company in a report on Tuesday, July 22nd. Royal Bank Of Canada upped their target price on Repligen from $193.00 to $204.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 30th. Barclays assumed coverage on Repligen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $150.00 target price for the company. Finally, Evercore ISI reduced their target price on Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research note on Tuesday, July 8th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $169.45.

Insider Activity

In other news, Director Martin D. Madaus purchased 1,800 shares of the business's stock in a transaction dated Friday, August 8th. The stock was acquired at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the acquisition, the director directly owned 1,800 shares of the company's stock, valued at approximately $201,834. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.20% of the stock is owned by corporate insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.